![](/img/cover-not-exists.png)
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
Kudchadkar, Ragini, Ernst, Scott, Chmielowski, Bartosz, Redman, Bruce G., Steinberg, Joyce, Keating, Anne, Jie, Fei, Chen, Caroline, Gonzalez, Rene, Weber, JeffreyVolume:
4
Language:
english
Journal:
Cancer Medicine
DOI:
10.1002/cam4.363
Date:
May, 2015
File:
PDF, 644 KB
english, 2015